NASEM Public Workshop to Discuss Applications of GLP-1R Agonists
The National Academies of Sciences, Engineering, and Medicine (NASEM) is hosting a Sept. 10 day-long workshop to discuss the impact of glucagon-like peptide-r receptor (GLP-1R) agonists on central nervous system disorders, including neurodegenerative diseases such as Parkinson’s.
The workshop will bring together experts from a number of disciplines, including neuroscience, pharmacology, medicine, and endocrinology. While GLP-1R agonists are best known for treating type 1 diabetes and to aid with weight loss, health-care professionals at the workshop will also discuss GLP-1R’s potential to treat dementia, alcohol and substance abuse disorders, and chronic pain, along with neurodegenerative diseases.
Boston Children’s AAC Program Seeks Input from PALS, ALS Clinicians
The Jay S. Fishman ALS Augmentative Communication Program at Boston Children’s Hospital is asking for input on the future impact of AI on augmentative and alternative communication (AAC), specifically related to amyotrophic lateral sclerosis (ALS).
The AAC program has launched a survey for people living with ALS (PALS); their caregivers and family members; and clinicians who work with them.
Watch an introductory video that explains the project’s goals — which include developing AAC that can more rapidly and accurately communicate in real time with the help of AI — and then take the survey, which consists of 33 questions for PALS; 15 questions for caregivers/family; and 18 questions for clinicians.
